Innovation in European healthcare – what can Sweden learn? - LIF

Implementation and use of innovatis
drugs in the outpatient sector: AMNOG
Introduction of a new
drug
(pharmaceutical
company)
Dossier
IQWiG:
Assessment in
comission from
the G-BA
G-BA: Assessment
of additional
benefit ofthe new
drug
New assessment possible or withdrawal from the German market
G-BA: Assessment
of additional
benefit ofthe new
drug
Additional
benefit:
Discount
negotiations
between GKV-SV
and pharmaceutical
company
No
agreemen
t
Arbitration
commission defines
the reimbursement
price
Not
accepted
Price set by the
pharmaceutical
company
Publishing of the
results of the
assessment
Publishing
of the G-BA
resolution
Agreement
Discount agreed
upon
accepted
Defined
reimbursement
price
3 month
6 month
12 month
15 month
No additional benefit:
Drug becomes part of reference
price system
58